New drug cocktail aims to tackle Hard-to-Treat cancers

NCT ID NCT06244485

Ongoing Disease control Sponsor: Daiichi Sankyo Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 22, 2026 · Updated 3 times

Summary

This early-stage trial is testing whether combining valemetostat tosylate with two different antibody-drug conjugates (T-DXd or Dato-DXd) is safe and effective for people with advanced solid tumors. About 210 adults with at least one measurable tumor will receive the drugs orally and by IV. The study looks for side effects and tumor shrinkage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: valemetostat tosylate combined with either T-DXd (Enhertu) or Dato-DXd
What this could lead to: If successful, this could point toward a new combination treatment for advanced solid tumors that are hard to treat.
What could go wrong: This is an early Phase 1b trial, so safety and effectiveness are not yet proven. The combination may cause unexpected side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer gastric adenocarcinoma gastroesophageal junction adenocarcinoma non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Locations

Aichi Cancer Center Hospital

Nagoya, 464-8681, Japan
Brcr Medical Center, Inc Dba Boca Raton Clinical Research

Plantation, Florida, 33322, United States
City of Hope At Orange County Lennar Foundation Cancer Center

Irvine, California, 92618, United States
Clinical Research Alliance

Westbury, New York, 11590, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Fred Hutchinson Cancer Center

Seattle, Washington, 98109, United States
Harbin Medical Univeristy Cancer Hospital

Heilongjiang, 150081, China
Hunan Cancer Hospital

Hunan, 410013, China
IRCCS Istituto Scientifico Romagnolo Per

Cesena, 47014, Italy
Jilin Cancer Hospital

Jilin City, 130000, China
Jinana Center Hosptial

Shandong, 240013, China
Kanagawa Cancer Center

Yokohama, 241-8515, Japan
Kindai University Hospital

Ōsaka-sayama, 589-8511, Japan
Mary Crowley Cancer Research Centers

Dallas, Texas, 75230, United States
Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
Memorial Sloan-Kettering Cancer Center (Mskcc) - New York

New York, New York, 10065, United States
National Cancer Center Hospital

Chūōku, 104-0045, Japan
National Cancer Center Hospital East

Kashiwa, 277-8577, Japan
National Hospital Org-Kyushu Cancer Center

Fukuoka, 811-1395, Japan
Next Virginia

Fairfax, Virginia, 22031, United States
Osaka International Cancer Institute

Osaka, 540-0008, Japan
Osaka University Hospital

Suita, 565-0871, Japan
Peking University Third Hospital

Beijing, 100191, China
Providence Portland Medical Center

Portland, Oregon, 97213, United States
Sharp Memorial Hospital

San Diego, California, 92123, United States
Shizuoka Cancer Center

Shizuoka, 411-8777, Japan
Sun Yat-Sen University, Cancer Center

Guangzhou, 510060, China
SunYat-Sen University Cancer Center

Guangzhou, 510060, China
The Cancer Institute Hospital of Jfcr

Kōtoku, 135-8550, Japan
The Cleveland Clinic Foundation

Cleveland, Ohio, 44195, United States
Unc Hospitals

Chapel Hill, North Carolina, 27514, United States
University of Chicago Medical Center

Chicago, Illinois, 60637, United States
University of Hawaii At Manoa

Honolulu, Hawaii, 96813, United States
University of Texas M. D. Anderson Cancer Center

Houston, Texas, 77030, United States
Ut Southwestern Medical Center

Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.